However, to determine the ability of IgTT-4E1-S to restrict 4-1BB costimulation to EGFR-expressing tumors while minimizing off-target costimulation, further studies are required in cancer cell lines expressing different levels of EGFR and PD-L1, as well as in humanized mouse models carrying patient-derived xenografts. This evidence concerns the gene EGFR and cancer.